10-Q: Nutriband Reports Reduced Quarterly Loss Amidst Revenue Growth and Strategic Development in Abuse-Deterrent Transdermal Products

Nutriband Inc. announced a narrower net loss and increased revenue for the quarter ended April 30, 2025, driven by growth in its contract manufacturing segment, despite continued cash burn and ongoing reliance on external financing for its AVERSA drug development pipeline.

Summary

• Nutriband Inc. reported a net loss of $1,388,869, or $(0.12) per share, for the three months ended April 30, 2025, a significant improvement from the $1,898,077 net loss, or $(0.21) per share, in the same period last year.
• Revenue increased by 63.4% to $667,432 for the quarter ended April 30, 2025, up from $408,532 in the prior year, primarily driven by the Pocono Pharmaceuticals segment's contract manufacturing services.
• Gross profit rose to $251,981 for the current quarter, compared to $164,786 in the prior year, attributed to higher margins in the sales mix.
• Research and development (R&D) expenses decreased to $683,426 from $974,535, mainly due to a reduction in labor costs.
• Selling, general and administrative (SG&A) expenses also decreased to $982,052 from $1,079,728, primarily due to lower non-cash equity-based expenses.
• Cash and cash equivalents stood at $2,964,097 as of April 30, 2025, a decrease from $4,311,719 at January 31, 2025.
• The company used $1,336,972 in cash from operating activities during the quarter, an increase from $833,926 used in the prior year period.
• The agreement with Kindeva Drug Delivery for AVERSA Fentanyl development was amended, reducing the remaining budget through NDA submission to $3.2 million in exchange for a $3.0 million milestone payment upon FDA approval.
• Nutriband is currently a defendant in a lawsuit seeking over $500,000 in damages plus punitive damages, with the company denying allegations and initiating counterclaims for $1,000,000 per claim.
• Management believes that substantial doubt about the company's ability to continue as a going concern is alleviated, expecting sufficient funds from operations for the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant revenue growth and a reduced net loss, indicating operational improvements in the manufacturing segment. However, this is tempered by continued substantial cash burn from operations, declining cash reserves, and explicit statements about the need for future capital raises, which will likely lead to dilution. Ongoing legal proceedings and identified material weaknesses in internal controls also add a layer of caution.

Positives

• Revenue increased significantly by 63.4% to $667,432 for the three months ended April 30, 2025, compared to the same period in 2024.
• Net loss decreased to $1,388,869, or $(0.12) per share, a notable improvement from $1,898,077, or $(0.21) per share, in the prior year.
• Gross profit increased to $251,981, reflecting higher margins in the sales mix.
• Research and development expenses decreased by approximately 30% to $683,426, indicating cost management in development activities.
• Selling, general and administrative expenses decreased by approximately 9% to $982,052, primarily due to reduced non-cash equity-based expenses.
• Interest income saw a substantial increase to $30,508, primarily due to investment of excess cash from prior equity financing.
• The amended agreement with Kindeva Drug Delivery for AVERSA Fentanyl reduces immediate development costs, with a significant milestone payment contingent on FDA approval.
• Management has added qualified accounting personnel and improved internal controls to address previously identified material weaknesses.

Negatives

• Cash and cash equivalents decreased by approximately $1.35 million from $4,311,719 at January 31, 2025, to $2,964,097 at April 30, 2025.
• Working capital decreased from $3,811,420 at January 31, 2025, to $2,504,596 at April 30, 2025.
• Net cash used in operating activities increased to $1,336,972 for the three months ended April 30, 2025, compared to $833,926 in the prior year, indicating a higher cash burn rate.
• The 4P Therapeutics segment generated no sales in the current quarter due to a shift in focus and the main contract winding down.
• The company has generated operating losses since its inception and continues to rely on sales of securities and debt to support cash flow.
• Material weaknesses in internal controls persist, specifically regarding the absence of segregation of duties and reliance on third-party consultants for certain accounting functions.
• The company is a defendant in a lawsuit seeking over $500,000 in damages, with counterclaims of $1,000,000 per claim, indicating ongoing legal exposure and potential costs.

Risks

• Economic uncertainty and current political/economic conditions in the U.S. and global economies may affect costs, timing of FDA approvals, pricing strategy, promotional activities, profitability, and margins.
• Market instability could make it difficult to accurately forecast future product demand trends.
• Inflationary factors, such as increases in product purchase costs, product rights acquisition, and overhead costs, may adversely affect operating results.
• The company faces risks common to low-revenue start-up enterprises, including undercapitalization, cash shortages, and limitations with personnel and capital expenditures.
• Drug development companies typically incur substantial losses during product development and FDA testing phases and do not generate revenues until after FDA approval, which is not assured.
• There is no assurance that the company will be able to operate profitably or generate positive cash flow, potentially leading to cessation of operations and total loss of investment.
• The company has not completed the development of its lead product (AVERSA Fentanyl) and has no product currently marketable in the United States.
• Expenses may increase beyond expectations and product approval timing may be delayed if additional studies are required by regulatory authorities.
• The company's stock price has been and is likely to continue to be volatile, and shareholders may not be able to resell shares at or above their purchase price.
• Future equity offerings and other issuances of common stock or other securities may result in significant dilution for stockholders.
• The drug delivery industry is subject to rapid technological change, and failure to keep up with developments may impair the company's ability to market its products.

Future Outlook

Nutriband expects an increase in demand for its Pocono Pharmaceuticals segment for the remainder of the current year. Management believes that sufficient funds will be generated from operations over the next twelve months to fund its activities, alleviating concerns about its ability to continue as a going concern. However, the company anticipates incurring substantial expenses as it continues with product development and clinical trials for its AVERSA pipeline, with potential for increased costs and delays if additional regulatory studies are required.

Management Comments

• "Management has prepared estimates for operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Companys ability to continue operations as a going concern."
• "Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment."
• "The revenue from the Pocono Pharmaceuticals segment increased from the prior year as the Company ordered additional equipment to meet the new demand and implemented this equipment during the third quarter of the prior year. An increase in demand is expected in the balance of the current year."
• The decrease in research and development expenses is primarily attributable to a reduction in labor costs.
• The increase in interest income is primarily due to investment in excess cash from the Company's equity financing.

Industry Context

Nutriband operates in the specialized and high-risk sector of transdermal pharmaceutical product development, particularly focusing on abuse-deterrent technologies for controlled substances like opioids and stimulants. This addresses a significant public health challenge. The company's dual business model, combining pharmaceutical R&D (4P Therapeutics) with contract development and manufacturing services (Pocono Pharmaceuticals), provides some revenue diversification. Its partnership with Kindeva Drug Delivery, a prominent CDMO, is a common strategy for smaller biotech firms to leverage established manufacturing and clinical expertise. The ongoing R&D losses and reliance on external capital are typical for companies in the pre-commercialization phase of drug development, where significant investment is required before potential market entry and profitability.

Comparison to Industry Standards

• Nutriband's continued operating losses and reliance on external financing are consistent with the typical financial profile of early-stage drug development companies, which often incur substantial R&D expenses for years before generating significant revenue from approved products.
• The company's focus on abuse-deterrent transdermal technology, particularly for opioids, aligns with a growing industry trend and regulatory push for safer drug formulations, similar to efforts by companies developing tamper-resistant opioid formulations.
• The partnership with Kindeva Drug Delivery, a former 3M Drug Delivery unit, indicates collaboration with a reputable contract development and manufacturing organization (CDMO), a common practice in the pharmaceutical industry to outsource specialized manufacturing and clinical supply needs.
• While the reduction in R&D expenses is positive for the income statement, a sustained decrease in R&D spending could be a concern for a drug development company, potentially signaling a slower pace of pipeline advancement compared to more aggressively funded peers in the biotech sector.
• The identified material weaknesses in internal controls, particularly regarding segregation of duties and reliance on third-party consultants, are below industry best practices for publicly traded companies, which typically emphasize robust internal control environments to ensure financial reporting reliability.

Corporate Governance

Legal Proceedings

• The company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP in the Supreme Court of the State of New York, New York County (Index No.654633/2023).
• Allegations include breach of contract, fraudulent activities, and tortious interference following the termination of an engagement letter for a public stock offering.
• Joseph Gunnar, LLC is seeking over $500,000 in damages plus punitive damages, while Lucosky Brookman LLP is demanding reimbursement of legal fees.
• The company denies all allegations, asserting the engagement letter was unenforceable and its termination was legally justified.
• Nutriband has initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, seeking $1,000,000 for each claim.
• The case is currently in the discovery stage with no pending hearings or motions.
• Plaintiffs proposed a settlement offer of $100,000 in early 2024, to which the company has not responded.

Related Party Transactions

• No related party transactions occurred during the three months ended April 30, 2025.
• During the three months ended April 30, 2024, options to purchase 390,000 shares of common stock were issued to executives and employees, with a fair value of $422,955.
• The $8,400,000 equity financing completed on April 19, 2024, included $7,120,000 from related parties, specifically a director and entities controlled by investors.
• During the three months ended April 30, 2024, the company received $300,000 from a credit line facility with TII Jet Services LDA, a related party.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity offerings needed to fund operations and product development; stock price volatility is expected; risk of total loss if the company cannot achieve profitability or secure necessary funding.
• **Employees**: Benefit from stock options as part of compensation; employment agreements for key executives automatically renew, providing stability.
• **Customers**: Customers of Pocono Pharmaceuticals benefit from increased capacity due to new equipment and expected higher demand for contract manufacturing services.
• **Creditors**: The company has outstanding notes payable and a secured borrowing liability related to a bankruptcy claim, indicating ongoing financial obligations.
• **Regulatory Authorities (FDA)**: The company's primary pharmaceutical products are subject to FDA approval, which is critical for market entry and future revenue generation, making regulatory outcomes a key determinant of success.

Next Steps

• Continue product development and clinical trials for AVERSA Fentanyl and other pipeline products (AVERSA Buprenorphine, AVERSA Methylphenidate).
• Kindeva Drug Delivery to perform commercial manufacturing process development and manufacturing of clinical supplies for the human abuse liability clinical study for AVERSA Fentanyl.
• Kindeva to develop chemistry, manufacturing and controls (CMC) information required by the FDA in support of a New Drug Application (NDA) for AVERSA Fentanyl.
• Address and resolve the ongoing lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP, currently in the discovery stage.
• Continue to implement improvements to internal controls over financial reporting, particularly regarding segregation of duties and reliance on third-party consultants.
• Monitor and manage cash flow, potentially seeking additional capital if needed to fund operations and development programs.

Key Dates

Recommendation

Keywords

Nutriband, AVERSA, transdermal patches, drug delivery, pharmaceutical development, FDA approval, fentanyl, buprenorphine, methylphenidate, Kindeva Drug Delivery, contract manufacturing, biotechnology, healthcare, quarterly report, SEC filing